Literature DB >> 21720026

Poly(amidoamine) dendrimers increase antifungal activity of clotrimazole.

Katarzyna Winnicka1, Katarzyna Sosnowska, Piotr Wieczorek, Pawel Tomasz Sacha, Elzbieta Tryniszewska.   

Abstract

Clotrimazole (CLO) is a local imidazolic antifungal agent. A major problem associated with the successful formulation of effective dosage forms containing CLO is its poor aqueous solubility, which presents a hindrance for the local availability of CLO and limits the effective antifungal therapy. In the present study, the effects of various concentrations of poly(amidoamine) (PAMAM) dendrimers generation 2 (G2) and generation 3 (G3) with amine (PAMAM-NH(2)) or hydroxyl surface groups (PAMAM-OH) on aqueous solubility and antifungal activity of CLO were studied. The obtained results showed that all tested PAMAM dendrimers improved the solubility of CLO and the more potent were PAMAM-NH(2) dendrimers. The increase in solubility of CLO was highest at dendrimer concentration of 10 mg/ml. Microbiology studies indicated that only PAMAM-NH(2) dendrimers significantly increased the antifungal activity of CLO (a 4-32-fold increase in the antifungal activity compared to pure CLO) and the most potent was dendrimer PAMAM-NH(2) G2. These observations indicate that PAMAM dendrimers might be considered as potential carriers of CLO and provide further impetus to evaluate these polymers for use in basic drug delivery studies and to design semisolid dosage forms based on dendrimers with antimicrobial drugs, like CLO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720026     DOI: 10.1248/bpb.34.1129

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  8 in total

1.  Evaluation of cationic polyamidoamine dendrimers' dermal toxicity in the rat skin model.

Authors:  Katarzyna Winnicka; Magdalena Wroblewska; Katarzyna Sosnowska; Halina Car; Irena Kasacka
Journal:  Drug Des Devel Ther       Date:  2015-03-05       Impact factor: 4.162

2.  Synthesis, characterization, and in vitro activity against Candida spp. of fluconazole encapsulated on cationic and conventional nanoparticles of poly(lactic-co-glycolic acid).

Authors:  Nicolás Gómez-Sequeda; Rodrigo Torres; Claudia Ortiz
Journal:  Nanotechnol Sci Appl       Date:  2017-05-16

Review 3.  New Advances in General Biomedical Applications of PAMAM Dendrimers.

Authors:  Renan Vinicius de Araújo; Soraya da Silva Santos; Elizabeth Igne Ferreira; Jeanine Giarolla
Journal:  Molecules       Date:  2018-11-02       Impact factor: 4.411

4.  Hydrogel of ketoconazole and PAMAM dendrimers: formulation and antifungal activity.

Authors:  Katarzyna Winnicka; Magdalena Wroblewska; Piotr Wieczorek; Pawel Tomasz Sacha; Elzbieta Tryniszewska
Journal:  Molecules       Date:  2012-04-18       Impact factor: 4.411

5.  Origanum majorana L. Essential Oil-Associated Polymeric Nano Dendrimer for Antifungal Activity against Phytophthora infestans.

Authors:  Vu Minh Thanh; Le Minh Bui; Long Giang Bach; Ngoc Tung Nguyen; Hoa Le Thi; Thai Thanh Hoang Thi
Journal:  Materials (Basel)       Date:  2019-05-04       Impact factor: 3.623

6.  Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells.

Authors:  Robert Czarnomysy; Anna Muszyńska; Jakub Rok; Zuzanna Rzepka; Krzysztof Bielawski
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 7.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08

Review 8.  Dendrimers and Dendritic Materials: From Laboratory to Medical Practice in Infectious Diseases.

Authors:  Miguel Ángel Ortega; Alberto Guzmán Merino; Oscar Fraile-Martínez; Judith Recio-Ruiz; Leonel Pekarek; Luis G Guijarro; Natalio García-Honduvilla; Melchor Álvarez-Mon; Julia Buján; Sandra García-Gallego
Journal:  Pharmaceutics       Date:  2020-09-14       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.